Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 7/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20825298 | 1.00 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL13884652 | 0.87 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL20815918 | 0.87 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL8080058 | 0.87 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL13893436 | 0.87 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL13884654 | 0.87 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL20825231 | 0.87 | CA1 (0.54) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL27175271 | 0.83 | CA1 (0.56) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17900900 | 0.78 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL18257501 | 0.76 | CA1 (0.55) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | CA1 2767/4885CA2 1093/4885CA7 395/4885 |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SF3B5, PRCP, GBA1 | CA1 2767/4885CA2 1093/4885CA7 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.